CVE-2025-62013 identifies a missing authorization vulnerability in POSIMYTH's UiChemy product, affecting all versions up to and including 4.0.0. The flaw arises because the application fails to properly enforce authorization checks on certain functions or endpoints, allowing users with low-level privileges (PR:L) to access resources or perform actions they should not be permitted to. The vulnerability is remotely exploitable (AV:N) without requiring user interaction (UI:N), increasing the risk of automated or remote attacks. The CVSS v3.1 base score is 4.3, reflecting a medium severity primarily due to limited confidentiality impact (C:L), with no impact on integrity (I:N) or availability (A:N). The scope remains unchanged (S:U), indicating the vulnerability affects only the vulnerable component. Although no known exploits are reported in the wild, the lack of authorization checks could be leveraged by attackers to gain unauthorized read access to sensitive information or configuration data within UiChemy, potentially aiding further attacks or reconnaissance. The vulnerability was published on October 22, 2025, with no patches currently linked, suggesting organizations must monitor vendor communications for updates. The affected product, UiChemy, is a solution developed by POSIMYTH, and the vulnerability could impact environments where this software is deployed, especially if exposed to untrusted networks or users. The technical details confirm the vulnerability is recognized and cataloged but currently lacks public exploit code or active exploitation reports.

For European organizations, the primary impact of CVE-2025-62013 is unauthorized access to sensitive data within the UiChemy application due to missing authorization controls. This could lead to limited confidentiality breaches, exposing internal information that may facilitate further attacks or data leakage. Since the vulnerability does not affect integrity or availability, the risk of data tampering or service disruption is low. However, unauthorized data access can still have regulatory and reputational consequences, especially under GDPR requirements for protecting personal and sensitive data. Organizations in sectors such as finance, healthcare, or critical infrastructure using UiChemy could face compliance risks and potential operational exposure. The remote exploitability without user interaction increases the threat surface, particularly if UiChemy instances are accessible over the internet or within large enterprise networks with multiple user roles. The absence of known exploits reduces immediate risk but does not eliminate the possibility of future attacks. Overall, the vulnerability represents a moderate risk that should be addressed promptly to maintain data confidentiality and regulatory compliance.

1. Immediately review and restrict network access to UiChemy instances, limiting exposure to trusted internal networks and known users only. 2. Implement strict access control policies and role-based access management to minimize privileges granted to users interacting with UiChemy. 3. Monitor logs and audit trails for unusual access patterns or unauthorized attempts to access restricted functions within UiChemy. 4. Engage with POSIMYTH to obtain official patches or updates addressing CVE-2025-62013 as soon as they become available and prioritize their deployment. 5. Until patches are applied, consider deploying web application firewalls (WAFs) or other security controls to detect and block unauthorized access attempts targeting UiChemy endpoints. 6. Conduct internal security assessments and penetration tests focusing on authorization controls within UiChemy to identify and remediate any additional weaknesses. 7. Educate system administrators and users about the risks associated with missing authorization and enforce strict credential management practices. 8. Maintain up-to-date backups and incident response plans to quickly respond if exploitation attempts are detected.